Myelodysplastic syndromes (MDS) with a deletion 5q display a specific immunophenotypic profile

被引：0
|
作者：
Oelschlaegel, U. [1 ]
Westers, T. M. [2 ]
Mohr, B. [1 ]
Parmentier, S. [1 ]
Sockel, K. [1 ]
Bornhaeuser, M. [1 ]
Van de Loosdrecht, A. A. [2 ]
Platzbecker, U. [1 ]
机构：
[1] Univ Hosp Dresden, Med Clin & Policlin 1, Dresden, Germany
[2] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70106-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-057
引用
收藏
页码：S47 / S48
页数：2
相关论文
共 50 条
  • [31] Deletion 5q MDS: Molecular and therapeutic implications
    Komrokji, Rami S.
    Padron, Eric
    Ebert, Benjamin L.
    List, Alan F.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (04) : 365 - 375
  • [32] Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies
    Giagounidis, Aristoteles
    List, Alan F.
    Hellstrom-Lindberg, Eva
    Mufti, Ghulam J.
    Schlegelberger, Brigitte
    Morrill, John
    Wu, Chengqing
    Skikne, Barry
    Fenaux, Pierre
    Goehring, Gudrun
    BLOOD, 2014, 124 (21)
  • [33] Molecular Dissection of the 5q Deletion in Myelodysplastic Syndrome
    Ebert, Benjamin L.
    SEMINARS IN ONCOLOGY, 2011, 38 (05) : 621 - 626
  • [34] A NEW CRITICAL DELETION OF 5Q IN MYELODYSPLASTIC SYNDROME
    PHILLIPS, CN
    PRIEST, JH
    VOGLER, WR
    CLINICAL RESEARCH, 1984, 32 (05): : A885 - A885
  • [35] Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
    Talati, Chetasi
    Sallman, David
    List, Alan
    SEMINARS IN HEMATOLOGY, 2017, 54 (03) : 159 - 166
  • [36] Cytogenetics of myelodysplastic syndromes and detection of del 5q
    Mufti, G.
    LEUKEMIA RESEARCH, 2007, 31 : S8 - S9
  • [37] Cryptic 5q deletion in a patient with myelodysplastic syndrome
    Medlock, Ruth
    Barrans, Sharon
    Cargo, Catherine
    Kelly, Richard
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (03) : 347 - 347
  • [38] Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
    List, Alan
    Dewald, Gordon
    Bennett, John
    Giagounidis, Aristotle
    Raza, Azra
    Feldman, Eric
    Powell, Bayard
    Greenberg, Peter
    Thomas, Deborah
    Stone, Richard
    Reeder, Craig
    Wride, Kenton
    Patin, John
    Schmidt, Michele
    Zeldis, Jerome
    Knight, Robert
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14): : 1456 - 1465
  • [39] Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
    Prebet, Thomas
    Cluzeau, Thomas
    Park, Sophie
    Sekeres, Mikkael A.
    Germing, Ulrich
    Ades, Lionel
    Platzbecker, Uwe
    Gotze, Katharina
    Vey, Norbert
    Oliva, Esther
    Sugrue, Mary M.
    Bally, Cecile
    Kelaidi, Charikleia
    Al Ali, Najla
    Fenaux, Pierre
    Gore, Steven D.
    Komrokji, Rami
    ONCOTARGET, 2017, 8 (47) : 81926 - 81935
  • [40] DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
    Gerds, A. T.
    List, A. F.
    Giagounidis, A.
    Hellstrom-Lindberg, E.
    Li, J. Shiansong
    Swern, A. S.
    Sugrue, M. M.
    Fenaux, P.
    Sekeres, M. A.
    LEUKEMIA RESEARCH, 2015, 39 : S109 - S109
12345